Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.
Wainberg
Mark A
MA
McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada. mark.wainberg@mcgill.ca
Brenner
Bluma G
BG
Turner
Dan
D
D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D009705:Nucleosides / Q000627:therapeutic use*; D009711:Nucleotides / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D009705:Nucleosides; D009711:Nucleotides; D018894:Reverse Transcriptase Inhibitors